212 related articles for article (PubMed ID: 21933224)
21. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
22. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies.
Bays HE
Endocr Pract; 2011; 17(6):933-8. PubMed ID: 21856592
[TBL] [Abstract][Full Text] [Related]
23. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
[TBL] [Abstract][Full Text] [Related]
24. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
26. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.
Yu M; Xu XJ; Yin JY; Wu J; Chen X; Gong ZC; Ren HY; Huang Q; Sheng FF; Zhou HH; Liu ZQ
Clin Pharmacol Ther; 2010 Mar; 87(3):330-5. PubMed ID: 20054294
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
[TBL] [Abstract][Full Text] [Related]
28. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
[TBL] [Abstract][Full Text] [Related]
29. Exenatide versus glibenclamide in patients with diabetes.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
[TBL] [Abstract][Full Text] [Related]
30. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
Gu W; Liang L; Wang S; Wang Y; Wu Y; Tian J; Yang G; Piao C; Li Y; Yin J; Xin X; Tan X; Ning G; Wang W;
J Diabetes; 2016 Nov; 8(6):809-815. PubMed ID: 26676908
[TBL] [Abstract][Full Text] [Related]
32. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
33. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
35. Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.
Wang S; Se YM; Liu ZQ; Lei MX; Hao-BoYang ; Sun ZX; Nie SD; Zeng XM; Wu J
Pharmazie; 2012 Jan; 67(1):74-9. PubMed ID: 22393835
[TBL] [Abstract][Full Text] [Related]
36. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
37. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index.
Zang H; Jiang F; Cheng X; Xu H; Hu X
Endocr J; 2018 Jul; 65(7):685-691. PubMed ID: 29669965
[TBL] [Abstract][Full Text] [Related]
38. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Goldstein BJ; Pans M; Rubin CJ
Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
[TBL] [Abstract][Full Text] [Related]
39. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
40. Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Strózik A; Stęposz A; Basiak M; Drożdż M; Okopień B
Pharmacol Rep; 2015 Feb; 67(1):24-31. PubMed ID: 25560571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
